Cargando…
Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403467/ https://www.ncbi.nlm.nih.gov/pubmed/35989682 http://dx.doi.org/10.1177/15330338221118413 |
_version_ | 1784773383475429376 |
---|---|
author | Xie, Danni Jin, Xin Sun, Rui Zhang, Meng Wang, Jiaxi Xiong, Xia Zhang, Xiaomei Zhao, Mingfeng |
author_facet | Xie, Danni Jin, Xin Sun, Rui Zhang, Meng Wang, Jiaxi Xiong, Xia Zhang, Xiaomei Zhao, Mingfeng |
author_sort | Xie, Danni |
collection | PubMed |
description | Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in recent years it has achieved a complete remission rate of approximately 90% in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Although CAR-T cell therapy has greatly alleviated the disease in patients with leukemia or lymphoma, some of them still relapse after treatment. Therefore, in this article, we discuss the factors that may contribute to disease relapse following CAR-T cell therapy and summarize potential strategies to overcome these obstacles, thus providing the possibility of improving standard treatment regimens. |
format | Online Article Text |
id | pubmed-9403467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-94034672022-08-26 Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies Xie, Danni Jin, Xin Sun, Rui Zhang, Meng Wang, Jiaxi Xiong, Xia Zhang, Xiaomei Zhao, Mingfeng Technol Cancer Res Treat Advances in CAR-T Cell Therapies for Cancer Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in recent years it has achieved a complete remission rate of approximately 90% in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Although CAR-T cell therapy has greatly alleviated the disease in patients with leukemia or lymphoma, some of them still relapse after treatment. Therefore, in this article, we discuss the factors that may contribute to disease relapse following CAR-T cell therapy and summarize potential strategies to overcome these obstacles, thus providing the possibility of improving standard treatment regimens. SAGE Publications 2022-08-22 /pmc/articles/PMC9403467/ /pubmed/35989682 http://dx.doi.org/10.1177/15330338221118413 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Advances in CAR-T Cell Therapies for Cancer Xie, Danni Jin, Xin Sun, Rui Zhang, Meng Wang, Jiaxi Xiong, Xia Zhang, Xiaomei Zhao, Mingfeng Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies |
title | Relapse Mechanism and Treatment Strategy After Chimeric Antigen
Receptor T-Cell Therapy in Treating B-Cell Hematological
Malignancies |
title_full | Relapse Mechanism and Treatment Strategy After Chimeric Antigen
Receptor T-Cell Therapy in Treating B-Cell Hematological
Malignancies |
title_fullStr | Relapse Mechanism and Treatment Strategy After Chimeric Antigen
Receptor T-Cell Therapy in Treating B-Cell Hematological
Malignancies |
title_full_unstemmed | Relapse Mechanism and Treatment Strategy After Chimeric Antigen
Receptor T-Cell Therapy in Treating B-Cell Hematological
Malignancies |
title_short | Relapse Mechanism and Treatment Strategy After Chimeric Antigen
Receptor T-Cell Therapy in Treating B-Cell Hematological
Malignancies |
title_sort | relapse mechanism and treatment strategy after chimeric antigen
receptor t-cell therapy in treating b-cell hematological
malignancies |
topic | Advances in CAR-T Cell Therapies for Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403467/ https://www.ncbi.nlm.nih.gov/pubmed/35989682 http://dx.doi.org/10.1177/15330338221118413 |
work_keys_str_mv | AT xiedanni relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies AT jinxin relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies AT sunrui relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies AT zhangmeng relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies AT wangjiaxi relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies AT xiongxia relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies AT zhangxiaomei relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies AT zhaomingfeng relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies |